CA2177179C - Antagonists to chaperonin 10 - Google Patents

Antagonists to chaperonin 10 Download PDF

Info

Publication number
CA2177179C
CA2177179C CA002177179A CA2177179A CA2177179C CA 2177179 C CA2177179 C CA 2177179C CA 002177179 A CA002177179 A CA 002177179A CA 2177179 A CA2177179 A CA 2177179A CA 2177179 C CA2177179 C CA 2177179C
Authority
CA
Canada
Prior art keywords
epf
cpnl0
cells
antibodies
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002177179A
Other languages
English (en)
French (fr)
Other versions
CA2177179A1 (en
Inventor
Halle Morton
Alice Christina Cavanagh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
Original Assignee
University of Queensland UQ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPM8234A external-priority patent/AUPM823494A0/en
Application filed by University of Queensland UQ filed Critical University of Queensland UQ
Publication of CA2177179A1 publication Critical patent/CA2177179A1/en
Application granted granted Critical
Publication of CA2177179C publication Critical patent/CA2177179C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
CA002177179A 1993-11-30 1994-11-30 Antagonists to chaperonin 10 Expired - Fee Related CA2177179C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPM270593 1993-11-30
AUPM2705 1993-11-30
AUPM8234A AUPM823494A0 (en) 1994-09-16 1994-09-16 Diagnostic and therapeutic uses of chaperonin 10
AUPM8234 1994-09-16
PCT/AU1994/000742 WO1995015339A1 (en) 1993-11-30 1994-11-30 Antagonists to chaperonin 10

Publications (2)

Publication Number Publication Date
CA2177179A1 CA2177179A1 (en) 1995-06-08
CA2177179C true CA2177179C (en) 2006-10-17

Family

ID=25644587

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002177179A Expired - Fee Related CA2177179C (en) 1993-11-30 1994-11-30 Antagonists to chaperonin 10

Country Status (11)

Country Link
US (3) US6113899A (enExample)
EP (2) EP0731811B1 (enExample)
JP (3) JP3987104B2 (enExample)
AT (1) ATE282634T1 (enExample)
AU (2) AU684578B2 (enExample)
CA (1) CA2177179C (enExample)
DE (1) DE69434137T2 (enExample)
ES (1) ES2233938T3 (enExample)
NZ (2) NZ276670A (enExample)
PT (1) PT731811E (enExample)
WO (2) WO1995015338A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2233938T3 (es) * 1993-11-30 2005-06-16 The University Of Queensland Chaperonina 10.
WO1999002989A1 (en) * 1997-07-10 1999-01-21 Medical Research Council Chaperone fragments
US6007821A (en) * 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US6475490B1 (en) 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
AUPP823999A0 (en) * 1999-01-20 1999-02-11 University Of Queensland, The A treatment
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method
DK1399744T3 (da) * 2001-06-27 2008-09-22 Janssen Pharmaceutica Nv EPF-receptorassays, forbindelser og terapeutiske præparater
AU2002952492A0 (en) 2002-11-06 2002-11-21 Cbio Limited Chaperonin 10 immunosuppression
GB0226105D0 (en) * 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
JP2007517808A (ja) * 2004-01-16 2007-07-05 キュビオ リミテッド Ｔｏｌｌ様受容体誘導性のサイトカインおよびケモカイン分泌のシャペロニン１０調節
KR20080098579A (ko) * 2005-08-31 2008-11-11 씨바이오 리미티드 변형된 샤페로닌 10
AU2006303826B2 (en) * 2005-10-20 2012-07-19 Cbio Limited Treatment of hypersensitivity
KR20080075505A (ko) * 2005-10-20 2008-08-18 씨바이오 리미티드 과민증의 치료 방법
CA2644058C (en) * 2006-03-02 2016-08-09 Cbio Limited Regulation of immune responses by modulation of the function of antigen presenting cells
BRPI0911676A2 (pt) 2008-04-11 2016-11-29 Cbio Ltd polipeptídeo cpn10 isolado, ácido nucléico isolado, construção de expressão, célula hospedeira, anticorpo, composição farmacêutica, método para tratar ou prevenir uma doença, método para modular a sinalização do prr, método para modular a produção e/ou a secreção de um ou mais imunomoduladores, método para inibir a produção e/ou a secreção de um ou mais imunomoduladores, método de identificação de um composto que se liga a um polipeptídeo, método para rastrear um coposto e um ligante de prr e variante funcional, derivado, homólogo, análogo ou fragmento do polipeptídeo
CA2776874A1 (en) 2009-10-09 2011-04-14 Cbio Limited Chaperonin 10 variants
US20110243921A1 (en) * 2010-03-30 2011-10-06 Cbio Limited Prevention and treatment of cutaneous lupus erythematosus
KR101776013B1 (ko) * 2017-05-26 2017-09-07 (주)넥스젠바이오텍 항산화 활성 및 피부 세포 증식 효과가 증가한 열 충격 단백질 10과 브라제인 단백질의 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선용 화장료 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986005498A1 (en) * 1985-03-12 1986-09-25 University Of Queensland Method for detecting early pregnancy factor (epf) in mammals, purifying epf and method for producing a monoclonal antibody
AU599021B2 (en) * 1985-03-12 1990-07-12 University Of Queensland, The Method for detecting early pregnancy factor (epf) in mammals,purifying epf and method for producing a monoclonal antibody
WO1988004779A1 (en) * 1986-12-22 1988-06-30 University Of Queensland Method of treatment of mammals using antibodies to early pregnancy factor (epf)
AU1086988A (en) * 1986-12-22 1988-07-15 University Of Queensland, The Method of treatment of mammals using antibodies to early pregnancy factor (epf)
ES2233938T3 (es) * 1993-11-30 2005-06-16 The University Of Queensland Chaperonina 10.

Also Published As

Publication number Publication date
EP0731811A1 (en) 1996-09-18
AU684578B2 (en) 1997-12-18
US6113899A (en) 2000-09-05
WO1995015338A1 (en) 1995-06-08
NZ276670A (en) 1998-01-26
EP0731811A4 (en) 2003-05-28
EP0731811B1 (en) 2004-11-17
EP0733071A4 (en) 1997-02-26
ES2233938T3 (es) 2005-06-16
DE69434137T2 (de) 2005-12-01
JP3987104B2 (ja) 2007-10-03
NZ276672A (en) 1998-01-26
AU1103695A (en) 1995-06-19
US6417334B1 (en) 2002-07-09
AU684577B2 (en) 1997-12-18
AU1103495A (en) 1995-06-19
DE69434137D1 (en) 2004-12-23
JP3545408B2 (ja) 2004-07-21
ATE282634T1 (de) 2004-12-15
WO1995015339A1 (en) 1995-06-08
JP2004067698A (ja) 2004-03-04
EP0733071A1 (en) 1996-09-25
JPH09506431A (ja) 1997-06-24
US7358329B2 (en) 2008-04-15
PT731811E (pt) 2005-04-29
JP3986481B2 (ja) 2007-10-03
JPH09505811A (ja) 1997-06-10
US20030175280A1 (en) 2003-09-18
CA2177179A1 (en) 1995-06-08

Similar Documents

Publication Publication Date Title
US6417334B1 (en) Antagonists to chaperonin 10
Kummer et al. Production and characterization of monoclonal antibodies raised against recombinant human granzymes A and B and showing cross reactions with the natural proteins
JPH03197499A (ja) 腫瘍壊死因子結合蛋白
Husby et al. Amyloid fibril protein subunit,‘protein AS’: distribution in tissue and serum in different clinical types of amyloidosis including that associated with myelomatosis and Waldenström's macroglobulinaemia
Cavanagh Production in vitro of mouse early pregnancy factor and purification to homogeneity
IBRAHIM et al. Reproductive tract secretions and bull spermatozoa contain different clusterin isoforms that cluster cells and inhibit complement‐induced cytolysis
Goodfellow et al. Monoclonal antibodies reacting with murine teratocarcinoma cells.
US6117421A (en) Method for promoting cell growth and immunosuppression using chaperonin
US5702705A (en) Antibody methods for the treatment of a hormone-mediated disease
JP2718827B2 (ja) 分泌Ｍａｃ−２結合糖タンパク質
JPH04505614A (ja) タンパク質複合体
US5723582A (en) Antigen-specific human glycosylation inhibiting factor
WO1994015637A2 (en) Prevention of suppression of immune defense against cancer caused by the cancer-associated scm-recognition peptides
Sivapurapu et al. Efficacy of antibodies against Escherichia coli expressed chimeric recombinant protein encompassing multiple epitopes of zona pellucida glycoproteins to inhibit in vitro human sperm–egg binding
Evans et al. Identification of a vimentin‐like function associated molecule (FAM) on rat NK cells: evidence for receptor function
Pleau et al. [19] Thymulin
Tokuyama et al. Separation and comparison of human TL-like antigens and HLA (A, B, C) antigens expressed on cultured T cells
Hongo et al. Immunochemical characterization of rat testicular asparagine synthetase
US6387875B1 (en) Method of use for murine leukaemia inhibitory factor-binding protein (mLBP)
JPS61100598A (ja) 抗原性ペプチド化合物
WO1991015236A1 (en) Treatment of autoimmune diseases
JPH08196272A (ja) ハイブリドーマ２９ｄ３８
JPH08182497A (ja) ハイブリドーマ２７ｄ５７
Pizzonia Cell biology of the Tamm-Horsfall glycoprotein
Morrow The structure-function relationship of glucose-dependent insulinotropic polypeptide

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20131202